Effects on ethanol withdrawal hyperexcitability of chronic treatment with a competitive N-methyl-D-aspartate receptor antagonist.
The effects of the competitive N-methyl-D-aspartate receptor antagonist DL-(E)-2-amino-4-methyl-5-phosphonopentanoate carboxy-ethylester (CGP39551) on the hyperexcitability produced by withdrawal from chronic ethanol treatment were studied in mice, to which CGP39551 was given chronically with the ethanol. When an interval of 72 or 96 hr was left between the last of the repeated CGP39551 injections and withdrawal from ethanol, the severity of the ethanol withdrawal syndrome was increased. When shorter time intervals were left between the end of the CGP39551 treatment and the ethanol withdrawal, the chronic CGP39551 treatment protected against the withdrawal hyperexcitability. When a single low dose of CGP39551 was given immediately after ethanol withdrawal, the compound protected against the withdrawal hyperexcitability. It is therefore suggested that the protective effects of concurrent chronic treatment with CGP39551, seen when the shorter intervals were allowed, were caused by residual compound. The increased severity of withdrawal, when sufficient time was left for washout of CGP39551, suggests that chronic administration of CGP39551 increased the adaptive changes that cause or contribute to ethanol withdrawal hyperexcitability. The results differ from the previously reported effects of N-methyl-D-aspartate antagonists on ethanol tolerance, because this was reduced by concurrent chronic treatment. They are also in contrast with the effects of chronic dihydropyridine calcium channel antagonists, which decreased both the development of tolerance and the ethanol withdrawal syndrome, when given chronically, concurrently with the ethanol. Cessation of prolonged ethanol intake results in a period of neuronal hyperexcitability, described as the withdrawal or abstinence syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)
Ripley
T L
TL
Pharmacology Department, Medical School, University Walk, Bristol, England.
Little
H J
HJ
D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D004334:Drug Administration Schedule; D000431:Ethanol / Q000009:adverse effects*; D006234:Handling, Psychological; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D012640:Seizures / Q000139:chemically induced; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D013997:Time Factors
D016194:Receptors, N-Methyl-D-Aspartate; C064540:CGP 39551; D000431:Ethanol; D015763:2-Amino-5-phosphonovalerate